IRIDEX commences commercial shipment of IQ 532 laser systems

NewsGuard 100/100 Score

IRIDEX Corporation, (Nasdaq: IRIX) today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

"The time and effort we invested to perfect our core system platform and obtain regulatory approval for a family of laser products has made it possible to introduce the IQ 532 green laser within one year of shipping the IQ 577 yellow laser," commented Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX.  "Continuing with this platform approach, we look forward to the timely introduction of additional systems currently under development."

As with the IQ 577, the IQ 532 features dual port laser output as well as a graphic, touchscreen interface.  Dual port connectivity provides the physician with the added convenience and efficiency by permitting the exchange of multiple delivery devices with one-touch speed and simplicity.  Setup and use of the IQ 532 system for surgery is quick, easy and intuitive, thanks to its superior ergonomics and user interface.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel protocol developed to rapidly diagnose eye stroke and expedite care